Summit Therapeutics plc

Results from a Phase III study in China of Akeso and Summit Therapeutics’ ivonescimab in non-small cell lung cancer (NSCLC) are an encouraging sign for the PD-1/VEGF-targeting bispecific antibody’s pi

BioNTech made its name and fortune with its Pfizer-partnered COVID-19 vaccine, Comirnaty, but this year could be a turning point in its bid to diversify and become a major oncology company as well. Th

Summit Therapeutics and its partner Akeso have a commanding lead in the VEGF x PD-(L)1 bispecific cancer immunotherapy field, but BioNTech is also focused on being a major contender. Several key clini

Summit Therapeutics and Pfizer have unveiled a collaboration which could help them compete with leaders in one of the most promising cancer fields, namely combinations of immunotherapy (IO) and antibo